Article Figures & Data
Figures
- Fig. 1.
IEX analysis of trastuzumab charge variants resulting from in vitro stressing in PBS at 37°C. (A), (B), and (C) are from the direct injection of unstressed and 1 week- and 2 week–stressed preparations, and (D), (E), and (F) are from the same preparations after spiking into plasma followed by capture with an antitrastuzumab Affimer reagent.
- Fig. 2.
IEX analysis of pertuzumab charge variants resulting from in vitro stressing in PBS at 37°C. (A), (B), and (C) are from the direct injection of unstressed and 1 week- and 2 week–stressed preparations, and (D), (E), and (F) are from the same preparations after spiking into plasma followed by capture with an antipertuzumab Affimer reagent.
- Fig. 3.
IEX analysis of plasma samples from one patient at six timepoints after enrichment of trastuzumab (A) and pertuzumab (B) with the Affimer reagents. Day 0 refers to the day when the first plasma sample was collected from this patient (not a predose sample).
- Fig. 4.
IEX analysis of samples from eight different patients after enrichment of trastuzumab (A and B) and pertuzumab (C and D) with the Affimer reagents. (A) and (C) show the charge variant profile of trastuzumab and pertuzumab, between days 62 and 67, and (B) and (D) show the charge variant profile of trastuzumab and pertuzumab, respectively, between days 155 and 166
- Fig. 5.
Heatmaps showing similarity of trastuzumab (A) and pertuzumab (B) LC-UV traces between eight patients. Similarity score has a range between 0 (completely different LC-UV traces) and 1 (identical LC-UV traces). The order of LC-UV traces in rows and columns was arranged after hierarchical clustering. S1–S8, subjects 1–8.
Tables
Participants (n = 8) Age in years, median (IQR) 54.0 (41–59) Menopausal status, n (%) Pre/perimenopausal 5 (62.5%) Post 3 (37.5%) Clinical tumor stage, n (%) cT0 0 (0%) cT1 2 (25%) cT2 6 (75%) Clinical lymph node status, n (%) Negative 4 (50%) Positive 4 (50%) Stage, n (%) II 6 (75%) III 2 (25%) HER2 status, n (%) 3+ at IHC 8 (100%) ER status, n (%) Positive (≥10%) 4 (50%) Negative (<10%) 4 (50%) PR status, n (%) Positive (≥10%) 2 (25%) Negative (<10%) 6 (75%) Tumor grade, n (%) Grade 2 1 (12.5%) Grade 3 7 (87.5%) Histology, n (%) NST/ductal 8 (100%) Pathologic outcome, n (%) Pathologic complete response (ypT0/is, N0) 5 (62.5%) No pathologic complete response 3 (37.5%) ER, estrogen receptor; IHC, immunohistochemistry; IQR, interquartile range; NST, no special type; PR, progesterone receptor.
Data Supplement
- Supplemental Figures -
Supplemental Figure 1. Overlaid LC-UV traces of trastuzumab (plots A, B and C) and pertuzumab (plots D, E and F) extracted from the plasma of 8 patients at different time points.
Supplemental Figure 2. Hierarchical clustering of the heatmaps of Trastuzumab (A) and Pertuzumab (B) LCUV traces between 8 patients.
- Supplemental Figures -
